Member LoginDividend CushionValue Trap
|
Valuentum
Reports
Fundamental data is updated weekly, as of the prior weekend. Please download the Full Report and Dividend Report for
any changes.
Latest
Valuentum Commentary
Jun 17, 2014
Firms Leaving United States for More Reasonable Tax Rates Elsewhere
Medtronic is the latest firm to pursue tax inversion via its tie-up with Covidien. Importantly, however, the firm renewed its commitment to dividend growth shareholders, hiking the payout 9%. May 19, 2014
Merger Mania: AT&T Ties the Knot with DirecTV; Pfizer Ups Offer for AstraZeneca; Siemens Complicates Matters for GE
M&A activity continues to be robust across most sectors. Let’s take a look at three deals that continue to dominate headlines. May 3, 2014
Teva Pharma: Underpriced and Misunderstood
The generics pharma giant remains one of our top ideas. Apr 22, 2014
Big News in Big Pharma
Pfizer is looking to scoop up AstraZeneca, Valeant and Ackman eye Allergan, Eli Lilly and Novartis strike a deal in animal health, and Novartis picks up GSK’s oncology portfolio. Mar 21, 2014
Update: Digging Into the Valuentum Dividend Cushion
We explain our innovative, predictive, and forward-looking indicator that assesses the safety of a firm's future dividends. The Valuentum Dividend Cushion flashed a red flag for every firm that cut their dividend in our database. Feb 28, 2014
Thank you…
We can’t begin to tell you how much we appreciate feedback. Jan 27, 2014
Surveying Fourth Quarter Earnings at Health Care Firms
Though it may be difficult to focus on underlying equity fundamentals in the face of a volatile overall market environment, we think doing so is even more important under such circumstances. Let’s examine our thoughts on fourth-quarter earnings season in the health care space . Dec 20, 2013
Dividend Increases/Decreases for the Week Ending December 20
Let's take a look at dividend increases/decreases for the week ending December 20. Oct 29, 2013
Pfizer’s and Merck’s 3Q Performance
Let’s take a look at fundamental performance of Pfizer and Merck during the third quarter. Latest News and Media The High Yield Dividend Newsletter, Best Ideas
Newsletter, Dividend Growth Newsletter, Nelson Exclusive publication, and any reports, articles and content found on
this website are for information purposes only and should not be considered a solicitation to buy or sell any
security. The sources of the data used on this website are believed by Valuentum to be reliable, but the data’s
accuracy, completeness or interpretation cannot be guaranteed. Valuentum is not responsible for any errors or
omissions or for results obtained from the use of its newsletters, reports, commentary, or publications and accepts
no liability for how readers may choose to utilize the content. Valuentum is not a money manager, is not a
registered investment advisor and does not offer brokerage or investment banking services. Valuentum, its employees,
and affiliates may have long, short or derivative positions in the stock or stocks mentioned on this site.
|
|||||||||||||||||||||
Members should expect the initial Economic Castle™ ratings.